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Abstract
Phospholipids are normally asymmetrically distributed between leaflets of the plasma membrane, due to the activity of
 . 2qaminophospholipid translocase APT , a putative plasma membrane Mg -ATPase which is thought to selectively transport
 .phosphatidylserine PS and other aminophospholipids from outer to inner membrane leaflet. Although several candidate
proteins have been proposed to serve this function, positive identification awaits demonstration of their capacity to restore
APT activity to a cell line that is deficient in this process. This study describes a simple and rapid protocol for the
production and selection of mutant cell lines that are defective in APT activity and suitable for expression cloning of
cDNAs coding for candidate APT enzymes. By flow cytometry, we demonstrate the time-dependent uptake of NBD-labeled
 .PS, but not phosphatidylcholine PC , by the mouse fibroblast cell line SV-T2. This uptake was inhibited by known
inhibitors of APT, including o-vanadate and N-ethylmaleimide, and by ATP-depletion. SV-T2 cells were mutagenized with
ethyl methanesulfonate, and APT-deficient cells were isolated by fluorescence activated cell sorting using NBD-PS as
substrate. From a total of 7.2P106 cells passed through the flow cytometer, 98 clones exhibited APT activity that was less
than 50% of that observed for wild-type SV-T2 cells. One clone which exhibited F25% of that observed for wild-type
cells, mutant M2711, was further characterized. The defect in mutant M2711 was specific for NBD-PS, and cellular ATP
was unchanged, suggesting that the defect in APT activity was not due to a decrease in cellular ATP levels. Mutant M2711
exhibited a growth pattern indistinguishable from that of wild-type SV-T2 cells, and SV-40 large T antigen, which is needed
for efficient episomal replication of plasmids containing the SV40 origin of replication, was unchanged. Finally, transfection
of M2711 with cDNAs for marker membrane proteins consistently resulted in the same high level of protein expression as
that observed for identically-transfected wild-type SV-T2. Thus, flow cytometry can be used for rapid identification of
mutants with defects in phospholipid transport that are suitable for functional reconstitution by transfection with candidate
APT cDNAs.
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1. Introduction
 .1The plasma membrane phospholipids PL of eu-
karyotic cells are normally asymmetrically dis-
tributed: the aminophospholipids phosphatidylserine
 .PS and phosphatidylethanolamine are oriented to-
wards the cytoplasm, whereas phosphatidylcholine
 .PC and sphingomyelin primarily reside in the exo-
w xplasmic leaflet 1–3 . Maintenance of this asymmet-
ric distribution of plasma membrane phospholipids is
central to the regulation of intracellular enzymatic
reactions, cell-cell interactions, phagocytosis of aged
w xor apoptotic cells, and blood coagulation 4,5 . It is
now generally accepted that the generation and main-
tenance of this asymmetric distribution of lipid be-
tween the inner and outer leaflets of the plasma
membrane arises through the activity of a lipid trans-
port protein with specificity for aminophospholipids.
 .This aminophospholipid translocase APT has been
shown to selectively transport PS and phos-
phatidylethanolamine, but not PC, from outer to inner
leaflets of the plasma membrane in a Mg2q and
ATP-dependent process that is inhibited at elevated
w 2qxCa , and inactivated by sulfhydryl-reactivei
w x w xreagents 6–10 . Schroit and coworkers 11 have
presented evidence that the Rh protein shares features
of the APT, and have proposed that it provides APT
function. Nevertheless, the similarity of the Mg2q-,
ATP- and PS-dependence of APT to that observed
for the hydrolytic activities of Mg2q-ATPases sug-
gests that the APT is a member of this family of
w x 2qATPases 12–14 . In support of a role for a Mg -
w xATPase in translocase activity, Auland et al. 15
reported PS-specific transport for proteoliposomes
reconstituted with purified erythrocyte Mg2q-ATPase.
Recently, cDNA of a Mg2q-ATPase from bovine
chromaffine granules was cloned, and it has been
proposed that this enzyme belongs to a novel subfam-
w xily of P-type ATPases with APT activity 16 . Posi-
tive identification of this candidate ATPase as the
plasma membrane APT, however, awaits demonstra-
tion of the functional properties of the protein, includ-
ing the capacity of the cDNA encoding this protein to
restore APT activity in a translocase-deficient cell.
w xIn a recent study, Hanada and Pagano 17 used
fluorescence microscopy to identify a mutant CHO
cell displaying decreased incorporation of NBD-PS,
consistent with diminished APT activity. In this pa-
per, we describe adaptation of these methods to flow
cytometry, which enables rapid screening of large
numbers of mutagenized cells to identify those cells
that are deficient in aminophospholipid transport and
suitable for reconstitution of APT activity by trans-
fection with candidate APT cDNAs.
2. Materials and methods
2.1. Materials
 w w1-caproyl-C12-NBD-PS 1-caproyl-2- 12- 7-nitro-
. x x2-1,3-benzoxadiazol-4-yl amino dodecanoyl -sn-
w x.glycero-3- phospho-L-serine , 1-palmitoyl-C6-NBD-
 w wPS 1-palmitoyl-2- 6- 7-nitro-2-1,3-benzoxadiazol-
. x x w4-yl amino caproyl -sn-glycero-3- phospho-L-
x.  wserine , 1-caproyl-C12-NBD-PC 1-caproyl-2- 12-
w . x7-nitro-2-1,3-benzoxadiazol-4-yl amino dode-
x .canoyl -sn-glycero-3-phosphocholine , and 1-palmi-
 w wtoyl-C6-NBD-PC 1-palmitoyl-2- 6- 7-nitro-2-1,3-
. x xbenzoxadiazol-4-yl amino caproyl -sn-glycero-3-
.phosphocholine were from Avanti Polar Lipids
 .Alabaster, AL . Mouse fibroblast cell line SV-T2
 .ATCC 163.1 was from American Type Culture
 .Collection Rockville, MD . DMEM and Opti-MEM
culture media were from GibcoBRL Gaithersburg,
.MD . Vector pcDNA3 was from Invitrogen Corp.
 .San Diego, CA . Murine mAb 10G10 was a gener-
ous gift from Dr. Marilyn J. Telen Duke University
.School of Medicine, Durham, NC . Murine mAb
against SV40 large T antigen was from Oncogene
 .Science Uniondale, NY . Calf serum, FBS, BSA,
Cell Dissociation Solution, EMS ethyl methanesul-
.fonate , and other common reagents were from Sigma
 .Chemical Co. St. Louis, MO .
2.2. Solutions
Solution 1: 137 mM NaCl, 2.7 mM KCl, 0.32 mM
Na HPO , 1.3 mM CaCl , 0.8 mM MgSO . pH 6.02 4 2 4
solution: Solution 1 containing 5.5 mM D-glucose, 20
mM acetate, pH 6.0. pH 7.4 solution: Solution 1
containing 5.5 mM D-glucose, 20 mM Hepes, pH 7.4.
dATP solution: Solution 1 containing 50 mM 2-de-
oxy-D-glucose, 5 mM NaN , 20 mM acetate, pH 6.0.3
DMEM complete medium: DMEM containing 10%
FBS, 5% calf serum, 2 mM glutamine, 100 Urml
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penicillin, 0.1 mgrml streptomycin. HBSS-1% BSA:
 .HBSS containing 1% vrv BSA.
2.3. APT acti˝ity assay
APT activity was measured using a modification
of the BSA back exchange method previously de-
w xscribed 17–19 . Although both 1-caproyl-C12-NBD-
PS and 1-palmitoyl-C6-NBD-PS could be used inter-
changeably, the former was taken up more rapidly by
w xthe cells 17 , and was used for the majority of
experiments as indicated in the figure legends. SV-T2
cells were grown to )50% confluence, and the cell
monolayers washed once with either pH 6.0 or pH
7.4 solution at 378C before addition of 1–5 mgrml
NBD-PL, which was freshly dispersed in pH 6.0 or
pH 7.4 solution from ethanol stock. The supernatant
volume was 125 ml, 200 ml, or 5 ml depending on
whether cell culture was performed in 48-well, 24-
well, or T75 culture flasks, respectively. Following
incubation at 378C for times indicated in the figure
legends, cells were placed on ice, 1% BSA was
added for 5 min, and then the monolayer was washed
twice to remove BSA and unincorporated NBD-PL.
Cells were lifted from the plastic by addition of Cell
Dissociation Solution and the cell-associated NBD-PL
measured by flow cytometry in a FACScan flow
 .cytometer Beckton-Dickinson . The light scatter
channels were set at linear, the fluorescence channel
at logarithmic gain, with a 530r30 bandpass filter in
the FL1 channel. The amount of NBD-PL transported
across the plasma membrane was derived from the
cell-associated NBD fluorescence measured for sam-
ples extracted with BSA, and expressed as a percent-
age of the total membrane-associated NBD derived
from matched samples incubated in the absence of
w xBSA 18,19 .
2.4. Treatment of cells with inhibitors of APT
In some experiments, cell monolayers were pre-
treated with known inhibitors of APT prior to mea-
 .surement of NBD-PL uptake: i cells were incubated
with 0.2 mM N-ethylmaleimide in DMEM complete
medium for 30 min at 48C, followed by incubation in
 .presence of 0.2 mM DTT for 10 min at 378C; or, ii
cells were incubated with 2 mM sodium o-vanadate
in DMEM complete medium for 15 min at 48C; or,
 .iii cells were incubated in dATP solution for 10 min
at 378C. In each case, cells identically incubated in
medium lacking inhibitors served as controls.
2.5. Production and cloning of APT-defecti˝e SV-T2
mutants
Six T75 flasks containing approximately 70% con-
fluent monolayers of SV-T2 cells were mutagenized
by incubation with 0.5 mgrml EMS in DMEM com-
plete medium for 18 h at 338C. After removal of
EMS, the cells were cultured an additional 5 days in
DMEM complete medium and then analysis of APT
activity was performed by 20 min incubation with
1-caproyl-C12-NBD-PS as described above see APT
.acti˝ity assay . After dissociation from the culture
flasks, the 1-caproyl-C12-NBD-PS loaded cells were
processed through a FACStar sorting flow cytometer
 . Beckton-Dickinson . A collection gate R1; see Fig.
.3 was set to exclude dead cells and cell debris, and
to include only those vital cells that failed to nor-
mally incorporate NBD-fluorescence. Following a re-
covery period of 2 days in culture, the sorted cells
were cloned by limiting dilution in 96-well plates,
and individual clones assayed for APT activity as
described above.
2.6. Cellular ATP assay
Cellular ATP was quantified using a biolumi-
nescence assay based on the luciferin-luciferase reac-
 .tion Bioluminescent Assay Kit, Sigma . SV-T2 cells
 . 3wild-type and M2711 mutants were plated at 10
cells per well in 96-well plates and cultured for 48 h
in DMEM complete medium. The adherent cells were
counted, gently washed with Opti-MEM, lysed by
addition of 100 ml Somatic Cell Releasing Reagent
and each lysate was immediately mixed with 100 ml
of luciferinrluciferase for ATP assay Luminometer
.Model TD-20e, Turner Designs, Sunnyvale, CA .
Calibration was performed with reference to 10 pmol
ATP standards added directly to each washed cell
monolayer immediately before lysis and assay. All
data were expressed as fmol ATP per cell.
2.7. Transfection of SV-T2 and mutant cells
 .SV-T2 cells wild-type and M2711 mutants were
identically transfected with cDNA for human CD59
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antigen cloned into the mammalian expression vector
w x 6pcDNA3 20 . Briefly, 8P10 cells in 800 ml of
Opti-MEM were transfected with 90 mg plasmid
DNA by electroporation using a Gene Pulser Bio-
.Rad at 360 V, 500 mF. Electroporated cells were
transferred to a T25 flask containing 10 ml of DMEM
complete medium, and grown to confluence by incu-
bation for 48-72 h at 338C. The cells were washed,
incubated with anti-CD59 mAb 10G10 10 mgrml in
.HBSS-1% BSA , and stained with FITC-labeled goat
anti-mouse IgG. All incubations were 30 min, room
temperature. Transfection efficiencies were deter-
mined from the number of CD59 antigen-positive
cells detected by flow cytometry, with comparison to
controls transfected with vector lacking an insert.
2.8. Measurement of SV40 large T antigen
 .SV-T2 cells wild-type and M2711 mutants were
detached from culture flasks by Cell Dissociation
 .Solution and fixed with acetonermethanol 1:1, vrv
followed by washing and suspension in HBSS-1%
5 BSA. For each assay, 2P10 cells were incubated 30
.min, 378C with 1 mgrml mAb against SV40 large
T-antigen antibody in 50 ml HBSS-1% BSA. The
cells were then washed and stained with 5 mgrml
FITC-labeled goat antibody to mouse IgG, and cell
fluorescence determined by flow cytometry, with cor-
rection for cell autofluorescence and non-specific
antibody binding.
3. Results and discussion
3.1. APT acti˝ity in SVT2 cells
The purpose of this study was to create a cell line
deficient in APT activity which could subsequently
be used as a target cell for functional reconstitution
by transfection with plasmid containing appropriate
cDNA. The mouse fibroblast cell line SV-T2 was
chosen for its short doubling time and high expres-
sion of SV-40 large T-antigen, which allows for
episomal replication to high copy numbers of vectors
containing the SV-40 origin of replication, such as
pcDNA3. In order to verify the presence of APT in
this cell before mutation, the cellular uptake of
NBD-labeled phospholipids was measured. For these
Fig. 1. APT-activity in SV-T2 cells. Cell monolayers of wild-type
SV-T2 in 48-well plates were washed once with pH 6.0 or pH 7.0
 .solution, respectively. 1-palmitoyl-C6-NBD-PS closed bars or
 .1-palmitoyl-C6-NBD-PC hatched bars was added to a final
 .concentration of 1 mgrml at pH indicated abscissa . Following
incubation for 20 min at 378C, cells were placed on ice and 1%
BSA was added to remove unincorporated NBD-PL. Cell-associ-
ated NBD-PL was measured by flow cytometry and NBD-PL
internalized expressed as percentage of total cell-associated NBD
 .fluorescence see Section 2 . Data of single experiment, represen-
tative of three so performed.
experiments, a modification of the BSA back ex-
change method was used to quantify cellular uptake
w xof NBD-PL 17–19 .
As demonstrated by the data of Fig. 1, incubation
with exogenous NBD-PS resulted in rapid uptake of
this lipid from the outer leaflet of the plasma mem-
brane into the cell. Consistent with the known speci-
ficity of APT for PS and other aminophospholipids,
uptake of NBD-PC was much less efficient, and
presumably represented random internalization of to-
tal plasma membrane lipid. After 20 min at pH 6.0,
)80% of exogenously added NBD-PS was inacces-
sible for extraction by BSA, interpreted as PS trans-
ported to the inner leaflet of the plasma membrane
through APT. Under the same conditions, uptake of
NBD-PC was less than 20%. As was previously
w xreported for CHO cells 17 , selective uptake of PS in
SV-T2 cells decreased to about 40% at pH 7.4. By
 .contrast, non-specific uptake of NBD-PC to the
inner leaflet was insensitive to pH, and did not
exceed 20% of membrane-incorporated label. There-
fore, NBD-PS uptake was routinely measured at pH
6.0 in all subsequent experiments, in order to maxi-
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Fig. 2. Effect of APT-inhibitors on NBD-PL uptake by wild-type SV-T2 cells. Untreated control SV-T2 cells, or cells pre-treated with
 .  .  .sodium o-vanadate thin solid line , N-ethylmaleimide thick solid line , or ATP-depleted in dATP solution dotted line , were incubated
with 1-caproyl-C12-NBD-PS, and uptake of NBD-PS was measured by flow cytometry as detailed in Section 2. Abscissa of histograms
denotes cell-associated NBD fluorescence after extraction of NBD-PL from outer plasma membrane leaflet, expressed on log scale.
 .  .Uptake of 1-caproyl-C12-NBD-PS dark grey histogram and 1-caproyl-C12-NBD-PC light grey histogram by uninhibited controls cells
are also shown. Data of single experiment, representative of two similar experiments
mize specific APT-mediated over non-specific up-
take.
In order to confirm that the observed uptake of
NBD-PS by SV-T2 cells was mediated by APT, cells
were treated with known inhibitors of APT, including
o-vanadate and the sulfhydryl reagent N-ethylmalei-
w xmide 8,9 , or they were depleted of ATP by incuba-
tion in the presence of the metabolic inhibitors 2-de-
oxyglucose and azide. As shown in Fig. 2, pretreat-
ment with any of these inhibitors of APT decreased
uptake of 1-caproyl-C12-NBD-PS, implying partici-
pation of APT in the measured loss of accessibility of
exogenous NBD-PS initially in the outer leaflet of the
plasma membrane. The marked decrease in NBD-PS
fluorescence retained by SV-T2 cells that had been
pretreated with inhibitors of the APT also suggested
the feasibility of using fluorescence activated flow
cytometry to isolate mutant SV-T2 cells exhibiting
partial or complete loss of APT activity.
3.2. Isolation and characterization of APT-defecti˝e
cell mutants
Wild-type SV-T2 cells were subjected to random
mutagenesis by treatment with the alkylating agent
EMS as described in Section 2. Following recovery
in culture medium free of mutagen for 5 days, cell
monolayers were incubated with 1-caproyl-C12-
NBD-PS for 20 min, and trypsinized for cell sorting
under conditions described in Fig. 3. In order to
Fig. 3. Isolation of APT-defective mutants by fluorescence acti-
vated cell sorting. Wild-type SV-T2 cells were mutagenized with
EMS as described in Section 2. Following loading with 1-
caproyl-C12-NBD-PS, cells were passed through a FACStar sort-
ing flow cytometer. Figure represents dot plot of cell-associated
 .NBD-PS fluorescence ordinate; log scale and forward light
 .scatter abscissa; linear scale obtained during sort. Rectangle
marked R1 denotes collection gate of selected cells retained for
 .subsequent cloning see Section 2 for details
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select for APT-deficient cells, a stringent sorting gate
for APT-deficient cells was selected, that excluded
)99.7% of the wild-type cells with normal APT
 .activity collection gate R1 depicted in Fig. 3 . From
a total of 7.2P106 cells passed through the flow
cytometer, 2P104 cells were collected in this gate,
and cloned by limiting dilution. Once the recovered
cells had grown to confluent monolayers, each clone
was tested for APT activity as indicated by specific
uptake of exogenous 1-caproyl-C12-NBD-PS. Of ap-
proximately 800 clones screened, 98 clones exhibited
APT activity that was less than 50% of that observed
for parental, non-mutagenized SV-T2 cells. A recent
study employed fluorescence microscopy to identify
a mutant CHO cell displaying decreased incorpora-
tion of NBD-PS, indicative of diminished APT activ-
w xity 17 . Adaptation of this selection method to fluo-
rescence-gated flow cytometry enabled us to expand
phenotypic analysis of APT activity from a total of
Fig. 4. APT activity of SV-T2 wild-type and M2711 mutant.
SV-T2 wild-type and M2711 mutant cells were incubated in
presence or absence of 2 mM sodium o-vanadate in DMEM
complete medium for 15 min at 48C. After one wash with pH 6.0
solution, 1-caproyl-C12-NBD-PS or 1-caproyl-C12-NBD-PC, re-
spectively, were added to the cells. Following incubation for 10
min at 378C, cells were placed on ice, 1% BSA was added, and
cell-associated NBD-PL was measured by flow cytometry see
. Section 2 . Each bar represents mean fluorescence"S.D. cor-
.rected for cell autofluorescence of 34 , with ns3. Data for
 .uptake of 1-caproyl-C12-NBD-PS closed bars 1 and 4 , 1-
 .caproyl-C12-NBD-PC open bars 2 and 5 , and 1-caproyl-C12-
 .NBD-PS in presence of o-vanadate hatched bars 3 and 6 are
shown. Data of single experiment, representative of four so
performed.
Table 1
ATP content of M2711 mutant
 .Cell ATP fmolrcell
aM2711 19.04"1.51
aWild-type 18.77"1.29
a  .Mean"S.D. ns5 .
20 000 in their study to )106 cellsrh of cell sorting
by flow cytometry, and to select deficient cell lines
on the basis of a quantitative assay of APT activity.
One APT mutant clone, M2711, was further charac-
terized. The results obtained for this mutant are illus-
trated by Fig. 4. As can be seen from these data,
M2711 cells exhibited -25% of the APT activity
observed for parental control SV-T2 cells. A further
decrease to negligible levels of 1-caproyl-C12-NBD-
PS was observed for both wild-type and mutant cells
upon pre-treatment with the APT inhibitor o-vana-
date. As the data represent single point measurements
following NBD-PS uptake after 10 min and not initial
velocities, the extent of the defect in APT is probably
underestimated. The defect appeared to be specific
Fig. 5. Growth curves for SV-T2 wild-type and mutant M2711
 .  .cells. SV-T2 wild-type B and M2711 mutant cells ^ were
plated into a 48-well plate at a density of 1500 cells per well in
DMEM complete medium and maintained in an incubator at
338C. Each day cells from three wells were detached by incuba-
tion with Cell Dissociation Solution, and counted by hemacy-
tometer. Data represent mean"S.D. Data of single experiment,
representative of two similar experiments.
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Fig. 6. Large T antigen expression in SV-T2 wild-type and
M2711 mutant cells. Cell monolayers of SV-T2 wild-type and
M2711 mutant were detached by incubation with Cell Dissocia-
 .tion Solution and fixed with acetonermethanol 1:1 . Large T
antigen was measured by flow cytometry as detailed in Section 2.
Histograms of cell-associated large T antigen fluorescence are
 . shown for SV-T2 wild-type dotted line , M2711 mutant solid
.  .line , and wild-type in absence of primary antibody dashed line .
Data of single experiment, representative of two similar experi-
ments.
for APT, as the uptake of 1-caproyl-C12-NBD-PC, a
lipid analog that is not translocated by APT, was
comparable for wild-type and mutant cells. Because
of the critical dependence of APT activity on cytoso-
lic ATP concentration, we considered the possibility
that the apparent decrease in APT observed for the
M2711 cell line related to a decrease in steady-state
ATP levels in this mutant cell. As shown in Table 1,
ATP content of M2711 did not significantly differ
from that measured for wild-type SV-T2, excluding
loss of APT activity due to decreased cytosolic ATP.
That the defect in APT activity observed in M2711
reflected specific loss of the APT enzyme, and was
not related to a general defect in cell metabolism
secondarily affecting APT activity, is also suggested
by the fact that the M2711 cell line exhibited a
growth pattern and doubling time indistinguishable
 .from that of the wild-type SV-T2 cells Fig. 5 .
Nevertheless, we cannot exclude the possibility that
the mutation produced in this cell affects another
membrane or membrane-interacting component that
secondarily reduces selective PS uptake through the
normal APT.
3.3. Recombinant protein expression in APT-defec-
ti˝e cells
In order for this cell to serve as a useful tool to
evaluate APT activity of candidate cDNAs that might
code for this enzyme, it was essential to establish that
chemical mutation of SV-T2 did not affect the level
of SV40-derived large T antigen that is needed for
efficient episomal replication of plasmids containing
the SV40 origin of replication. As shown in Fig. 6,
we detected the same level of large T antigen in
M2711 mutants as observed for wild-type SV-T2
Fig. 7. Recombinant gene expression in SV-T2 wild-type and M2711 mutant cells. SV-T2 wild-type and M2711 mutant cells were
 .transfected with cDNA for human CD59 in pcDNA3 vector, and cell surface-expressed CD59 ordinate was measured by flow cytometry
 .as detailed in Section 2. Dot plots of cell-associated CD59 fluorescence are shown for SV-T2 wild-type panel B and M2711 mutant cells
 .panel C . Data for SV-T2 wild-type cells transfected with pcDNA3 vector only are shown in panel A. An arbitrary gate is drawn to
facilitate comparison of percentage of transfected cells expressing CD59 antigen, above vector only controls in panel A. Data of single
experiment, representative of at least ten similar experiments.
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cells. Furthermore, transfection of M2711 with cD-
NAs for marker membrane proteins consistently re-
sulted in the same level of protein expression as
observed for identically-transfected wild-type SV-T2
 .cells Fig. 7 .
In summary, our study describes a simple and
rapid protocol for the production and selection of
mutant cell lines that are functionally deficient in
aminophospholipid transport, and suitable for stable
transfection. The phenotypic property of the M2711
mutant cell mimics selective inhibition of APT activ-
ity, as evidenced by a decrease in cellular uptake of
NBD-PS, but not NBD-PC, without obvious change
in metabolic or biosynthetic capacity. Identity of the
specific mutation introduced in this cell line and
other mutant cell lines that have been isolated using
this selection protocol awaits isolation of a specific
cDNA with capacity to restore APT activity upon
transfection into these cells.
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